Expression of syndecan-1 and E-cadherin is inversely correlated with poor patient's prognosis and recurrent status of extrahepatic bile duct carcinoma

Biomedical Research

Volumn 30, Issue 2, 2009, Pages 79-86

  Ohashi, Motonari ^a   Kusumi, Tomomi ^a   Sato, Fuyuki ^a   Kudo, Yasuyuki ^a   Jin, Hiroyuki ^a   Akasaka, Harue ^a   Miyamoto, Keiichi ^a   Toyoki, Yoshikazu ^a   Hakamada, Kenichi ^a   Kijima, Hiroshi ^a  

^a HIROSAKI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

SYNDECAN 1; UVOMORULIN; CADHERIN; SDC1 PROTEIN, HUMAN; TUMOR PROTEIN;

ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; CANCER INVASION; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; EXTRAHEPATIC BILE DUCT CARCINOMA; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROGNOSIS; ADENOCARCINOMA; BILE DUCT TUMOR; BIOSYNTHESIS; CELL ADHESION; DISEASE FREE SURVIVAL; GENE EXPRESSION REGULATION; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PREDICTION AND FORECASTING; SURVIVAL RATE; TUMOR RECURRENCE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BILE DUCT NEOPLASMS; CADHERINS; CELL ADHESION; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; SURVIVAL RATE; SYNDECAN-1;

EID: 67649743780     PISSN: 03886107     EISSN: 1880313X     Source Type: Journal    
DOI: 10.2220/biomedres.30.79     Document Type: Article

References (54)

1. Anttonen A, Heikkilä P, Kajanti M, Jalkanen M and Joensuu H (2001) High syndecan-1 expression is associated with favourable outcome in squamous cell lung carcinoma treated with radical surgery. Lung Cancer 32, 297-305.
2. Anttonen A, Kajanti M, Heikkilä P, Jalkanen M and Joensuu H (1999) Syndecan-1 expression has prognostic significance in head and neck carcinoma. Br J Cancer 79, 558-564.
3. Ashida K, Terada T, Kitamura Y and Kaibara N (1998) Expression of E-cadherin, alpha-catenin, beta-catenin, and CD44 (standard and variant isoforms) in human cholangiocarcinoma: an immumohistochemical study. Hepatology 27, 974-982.
4. Barbareschi M, Maisonneuve P, Aldovini D, Cangi MG, Pecciarini L, Angelo Mauri F, Veronese S, Caffo O, Lucenti A, Palma PD, Galligioni E and Doglioni C (2003) High syndecan-1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis. Cancer 98, 474-483.
5. Bayer-Garner IB and Smoller BR (2001) The expression of syndecan-1 is preferentially reduced compared with that of E-cadherin in acantholytic squamous cell carcinoma. J Cutan Pathol 28, 83-89.
6. Beauvais DM and Rapraeger AC (2004) Syndecans in tumor cell adhesion and signaling. Reprod Biol Endocrinol 2, 3.
7. Bernfeld M, Kokenyesi R, Kato M, Hinkes MT, Spring J Gallo RL and Lose EJ (1992) Biology of the syndecans: A family of transmembrane heparan sulfate proteoglycans. Annu Rev Cell Biol 8, 365-393.
8. Carey DJ (1997) Syndecans: multifunctional cell-surface co-receptors. Biochem J 327, 1-16.
9. Chen D, Adenekan B, Chen L, Vaughan ED, Gerald W, Feng Z and Knudsen BS (2004) Syndecan-1 expression in locally invasive and metastatic prostate cancer. Urology 63, 402-407.
10. Chu YQ, Ye ZY, Tao HQ, Wang YY and Zhao ZS (2008) Relationship between cell adhesion molecules expression and the biological behavior of gastric carcinoma. World J Gastroenterol 14, 1990-1996.
11. Conejo JR, Kleeff J, Koliopanos A, Matsuda K, Zhu ZW, Goecke H, Bicheng N, Zimmermann A, Korc M, Friess H and Büchler MW (2000) Syndecan-1 expression is up-regulated in pancreatic but not in other gastrointestinal cancers. Int J Cancer 88, 12-20.
12. David G (1993) Integral membrane heparan sulfate proteoglycans. FASEB J 7, 1023-1030.
13. Day RM, Hao X, Ilyas M, Daszak P, Talbot IC and Forbes A (1999) Changes in the expression of syndecan-1 in the colorectal adenoma-carcinoma sequence. Virchows Arch 434, 121-125.
14. DeOliveira ML, Cunningham SC, Cameron JL, Kamangar F, Winter JM, Lillemoe KD, Choti MA, Yeo CJ and Schulick RD (2007) Cholangiocarcinoma; Thirty-one-year experience with 564 patients at a single institution. Ann Surg 245, 755-762.
15. Fujiya M, Watari J, Ashida T, Honda M, Tanabe H, Fujiki T, Saitoh Y and Kohgo Y (2001) Reduced expression of syndecan-1 affects metastatic potential and clinical outcome in patients with colorectal cancer. Jpn J Cancer Res 92, 1074-1081.
16. Greene FL, Page DL, Fleming ID, Fritz A, Balch CM, Haller DG and Morrow M (2002) American Joint Committee on Cancer Staging Manual, 6th ed. Springer-Verlag, Tokyo.
17. Harada K, Masuda S, Hirano M and Nakanuma Y (2003) Reduced expression of syndecan-1 correlates with histologic dedifferentiation, lymph node metastasis, and poor prognosis in intrahepatic cholangiocarcinoma. Hum Pathol 34, 857-863.
18. Hasengaowa, Kodama J, Kusumoto T, Shinyo Y, Seki N and Hiramatsu. Y (2005) Prognostic significance of syndecan-1 expression in human endometrial cancer. Ann Oncol 16, 1109-1115.
19. Hirohashi S (1998) Inactivation of the E-cadherin-mediated cell adhesion system in human cancers. Am J Pathol 153, 333-339.
20. http://ganjoho.ncc.go.jp/professional/statistics/statistics.html (accessed 4 June 2008) Vital Statistics of Japan, Ministry of Health, Labour & Welfare
21. Ilyas M and Tomlinson IP (1997) The interactions of APC, E-cadherin and beta-catenin in tumor development and progression. J Pathol 182, 128-137.
22. Inki P, Joensuu H, Grènman R, Klemi P and Jalkanen M (1994). Association between syndecan-1 expression and clinical outcome in squamous cell carcinoma of the head and neck. Br J Cancer 70, 319-323.
23. Inki P, Stenbäck F, Grenman S and Jalkanen M (1994) Immunohistochemical localization of syndecan-1 in normal and pathological human uterine cervix. J Pathol 172, 349-355.
24. Ishihara S, Miyakawa S, Takada T, Takasaki K, Nimura Y, Tanaka M, Miyazaki M, Nagakawa T, Kayahara M and Horiguchi A (2007) Status of surgical treatment of biliary tract cancer. Dig Surg 24, 131-136.
25. Ito Y, Yoshida H, Nakano K, Takarnura Y, Miya A, Kobayashi K, Yokozawa T, Matsuzuka F, Matsuura N, Kuma K and Miyauchi A (2003) Syndecan-1 expression in thyroid carcinoma: stromal expression followed by epithelial expression is significantly correlated with dedifferentiation. Histopathology 43, 157-164.
26. Japanese Society of Biliary Surgery (2001) Classification of Biliary Tract Carcinoma. Kanehira & Co., Ltd., Tokyo.
27. Juuti A, Nordling S, Lundin J, Louhimo Jand Haglund C (2005) Syndecan-1 expression - a novel prognostic marker in pancreatic cancer. Oncology 68, 97-106.
28. Kato M, Saunders S, Nguyen H and Berrifield M (1995) Loss of cell surface syndecan-1 causes epithelia to transform into anchorage-independent mesenchyme-like cells. Mol Biol Cell 6, 559-576.
29. Kemler R (1993) From cadherins to catenins: cytoplasmic protein interaction and regulation of cell adhesion. Trend Genet 9, 317-321.
30. Kim CW, Goldberger OA, Gallo RL and Bernfield M (1994) Members of the syndecan family of heparan sulfate proteoglycans are expressed in distinct cell-, tissue-, and development-specific patterns. Mol Biol Cell 15, 797-805.
31. Kondo S, Takada T, Miyazaki M, Miyakawa S, Tsukada K, Nagino M, Furuse J, Saito H, Tsuyuguchi T, Yamamoto M, Kayahara M, Kimura F, Yoshitomi H, Nozawa S, Yoshida M, Wada K, Hirano S, Amano H and Miura F (2008) Guidelines for the management of biliary tract and ampullary carcinomas: surgical treatment. J Hepatobiliary Pancreat Surg 15, 41-54.
32. Kurokawa H, Zhang M, Matsumoto S, Yamashita Y, Tanaka T, Takamori K, Igawa K, Yoshida M, Fukuyama H, Takahashi T and Sakoda S (2006) Reduced syndecan-1 expression is correlated with the histological grade of malignancy at the deep invasive front in oral squarnous cell carcinoma. J Oral Pathol Med 35, 301-306.
33. Leivonen M, Lundin J, Nordling S, von Boguslawski K and Haglund C (2004) Prognostic value of syndecan-1 expression in breast cancer. Oncology 67, 11-18.
34. Leppä S, Vleminckx K, Van Roy F and Jalkanen M (1996) Syndecan-1 expression in mammary epithelial tumor cells is E-cadherin-dependent. J Cell Sci 109, 1393-1403.
35. Li HG, Xie DR, Shen XM, Li HH, Zeng H and Zeng YJ (2005) Clinicopathological significance of expression of paxillin, syndecan-1 and EMMPRIN in hepatocellular carcinoma. World J Gastroenterol 11, 1445-1451.
36. Loussouarn D, Campion L, Sagan C, Frenel JS, Dravet F, Classe JM, Pioud-Martigny R, Berton-Rigaud D, Bourbouloux E, Mosnier JF, Bataille FR and Campone M (2008) Prognostic impact of syndecan-1 expression in invasive ductal breast carcinomas. Br J Cancer 98, 1993-1998.
37. Malhi H and Gores GJ (2006) Cholangiocarcinoma: modern advances in understanding a deadly old disease. J Hepatol 45, 856-867.
38. Matsumoto A, Ono M, Fujimoto Y, Gallo RL, Bernfeld M and Kohgo Y (1997) Reduced expression of syndecan-1 in human hepatocellular carcinoma with high metastatic potential. Int J Cancer 74, 482-491.
39. Mikami S, Ohashi K, Usui Y, Nemoto T, Katsube K, Yanagishita M, Nakajima M, Nakamura K and Koike M (2001) Loss of syndecan-1 and increased expression of heparanase in invasive esophageal carcinomas. Jpn J Cancer Res 92, 1062-1073.
40. Mikami T, Saegusa M, Mitomi H, Yanagisawa N, Ichinoe M and Okayasu I (2001) Significant correlations of E-cadherin, catenin, and CD44 variant form expression with carcinoma cell differentiation and prognosis of extrahepatic bile duct carcinomas. Am J Clin Pathol 116, 369-376.
41. Mitselou A, loachim E, Peschos D, Charalabopoulos K, Michael M, Agnantis NJ and Vougiouklakis T (2007) Ecadherin adhesion molecule and syndecan-1 expression in various thyroid pathologies. Exp Oncol 29, 54-60.
42. Nackaerts K, Verbeken E, Deneffe G, Vanderschueren B, Demedts M and David G (1997) Heparan sulfate proteoglycan expression in human lung-cancer cells. Int J Cancer 74, 335-345.
43. Nagakawa T, Kayahara M, Ikeda S, Futakawa S, Kakita A, Kawarada H, Matsuno M, Takada T, Takasaki K, Tanimura H, Tashiro S and Yamaoka Y (2002) Biliary tract cancer treatment: results from the Biliary Tract Cancer Statistics Registry in Japan. J Hepalobiliary Pancreat Surg 9, 569-575.
44. Pignatelli M and Vessey CJ (1994) Adhesion molecules: novel molecular tools in tumor pathology. Hum Pathol 25, 849-856
45. Pulkkinen JO, Penttinen M, Jalkanen M, Klemi P and Grénman R (1997) Syndecan-1: a new prognostic marker in laryngeal cancer. Acta Otolapyngol 117, 312-315.
46. Sasaki R, Takahashi M, Funato O, Nitta H, Murakami M, Kawamura H, Suto T, Kanno S and Saito K (2001) Prognostic significance of lymph node involvement in middle and distal bile duct cancer. Surgery 129, 677-683.
47. Seyama Y and Makuuchi M (2007) Current surgical treatment for bile duct cancer. World J Gastroenterol 13, 1505-1515.
48. Shariat SF, Svatek RS, Kabbani W, Walz J, Lotan Y, Karakiewicz PI and Roehrborn CG (2008) Prognostic value of syndecan-1 expression in patients treated with radical prostatectomy. BJU Int 101, 232-237.
49. Shinyo Y, Kodama J, Hasengaowa, Kusumoto T and Hiramatsu Y (2005) Loss of cell-surface heparan sulfate expression in both cervical intraepithelial neoplasm and invasive cervical cancer. Gynecol Oncol 96, 776-783.
50. Soukka T, Pohjola J, Inki P and Happonen RP (2000) Reduction of syndecan-1 expression is associated with dysplastic oral epithelium. J Oral Pathol Med 29, 308-313.
51. Sun D, Mcalmon KR, Davies JA, Bernfeld M and Hay ED (1998) Simultaneous loss of expression of syndecan-1 and E-cadherin in the embryonic palate during epithelial-mesenchymal transformation. Int J Dev Biol 42, 733-736.
52. Takeichi M (1991) Cadherin cell adhesion receptors as a morphogenetic regulator. Science 251, 1451-1455.
53. Wijnhoven BP, Dinjens WN and Pignatelli M (2000) Ecadherin-catenin cell-cell adhesion complex and human cancer. Br J Surg 87, 992-1005.
54. Zimmermann P and David G (1999) The syndecans, tuners of transmembrane signaling. FASEB J 13 Suppl:S91-S100.